Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M et al. (2025)
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Blood (in press)
DOI 10.1182/blood.2025030113, PubMed 41060326

Smit AJT, Van der Maas NG, Van der Holt B, Van Norden Y, Van Werkhoven E, Vangsted AJ, Ypma PF, Visser-Wisselaar HA, Troia R, Boccadoro M, Löwenberg B, Janssen JJWM, Ossenkoppele GJ, Schjesvold F, Sonneveld P, Zweegman S, Versluis J, Cornelissen JJ (2025)
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology
Haematologica (in press)
DOI 10.3324/haematol.2025.288675, PubMed 41035401

Moore KLF, Rognvaldsson S, Szabo AG, Vaitekėnaitė V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH (2025)
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group
Haematologica (in press)
DOI 10.3324/haematol.2025.287344, PubMed 40905090